Northern Trust
DYN icon

Northern Trust’s Dyne Therapeutics DYN Stock Holding History

Northern Trust’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.7M Buy
1,198,838
+106,647
+10% +$1.84M ﹤0.01% 1632
2025
Q4 		$21.4M Buy
1,092,191
+54,623
+5% +$1.03M ﹤0.01% 1607
2025
Q3 		$13.1M Buy
1,037,568
+196,531
+23% +$2.24M ﹤0.01% 1953
2025
Q2 		$8.01M Buy
841,037
+118,575
+16% +$1.31M ﹤0.01% 2199
2025
Q1 		$7.56M Sell
722,462
-54,551
-7% -$780K ﹤0.01% 2203
2024
Q4 		$18.3M Buy
777,013
+55,511
+8% +$1.64M ﹤0.01% 1751
2024
Q3 		$25.9M Buy
721,502
+101,863
+16% +$4.05M ﹤0.01% 1465
2024
Q2 		$21.9M Buy
619,639
+72,604
+13% +$2.11M ﹤0.01% 1497
2024
Q1 		$15.5M Buy
547,035
+123,950
+29% +$2.8M ﹤0.01% 1768
2023
Q4 		$5.63M Buy
423,085
+28,834
+7% +$282K ﹤0.01% 2428
2023
Q3 		$3.53M Buy
394,251
+13,323
+3% +$144K ﹤0.01% 2642
2023
Q2 		$4.29M Buy
380,928
+106,455
+39% +$1.26M ﹤0.01% 2585
2023
Q1 		$3.16M Sell
274,473
-6,562
-2% -$85.2K ﹤0.01% 2725
2022
Q4 		$3.26M Buy
281,035
+14,454
+5% +$167K ﹤0.01% 2735
2022
Q3 		$3.39M Buy
266,581
+543
+0.2% +$6.23K ﹤0.01% 2720
2022
Q2 		$1.83M Buy
266,038
+9,374
+4% +$64.6K ﹤0.01% 3113
2022
Q1 		$2.47M Sell
256,664
-4,571
-2% -$38.9K ﹤0.01% 2990
2021
Q4 		$3.11M Buy
261,235
+4,023
+2% +$56.5K ﹤0.01% 2987
2021
Q3 		$4.18M Sell
257,212
-13,019
-5% -$231K ﹤0.01% 2844
2021
Q2 		$5.69M Buy
270,231
+94,786
+54% +$1.78M ﹤0.01% 2768
2021
Q1 		$2.72M Buy
175,445
+13,135
+8% +$254K ﹤0.01% 3086
2020
Q4 		$3.41M Buy
+162,310
New +$3.21M ﹤0.01% 2897

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Northern Trust's DYN Position: Q1 2026 in Review

Northern Trust increased its Dyne Therapeutics (DYN) stake by 9.8% in Q1 2026, buying an estimated $1.84M and bringing the position to 1,198,838 shares worth $21.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1632.

Northern Trust first reported a position in DYN in Q4 2020 and has held it in 22 quarters since. The position peaked at $25.9M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Northern Trust held 1,198,838 shares of Dyne Therapeutics worth $21.7M as of Q1 2026.
  • Northern Trust bought 106,647 Dyne Therapeutics shares in Q1 2026, an estimated $1.84M.
  • Dyne Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1632 holding.
  • Northern Trust first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Northern Trust's Dyne Therapeutics position peaked at $25.9M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.